283 related articles for article (PubMed ID: 38478329)
1. Ovarian Suppression: Early Menopause and Late Effects.
Molinelli C; Jacobs F; Nader-Marta G; Borea R; Scavone G; Ottonello S; Fregatti P; Villarreal-Garza C; Bajpai J; Kim HJ; Puglisi S; de Azambuja E; Lambertini M
Curr Treat Options Oncol; 2024 Apr; 25(4):523-542. PubMed ID: 38478329
[TBL] [Abstract][Full Text] [Related]
2. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
4. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
Azim HA; Davidson NE; Ruddy KJ
Am Soc Clin Oncol Educ Book; 2016; 35():23-32. PubMed ID: 27249683
[TBL] [Abstract][Full Text] [Related]
5. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O; Regan MM; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Perez EA; Ciruelos E; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Pinotti G; Puglisi F; Crivellari D; Ruhstaller T; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Bernhard J; Luo W; Ribi K; Viale G; Coates AS; Gelber RD; Goldhirsch A; Francis PA; ;
N Engl J Med; 2014 Jul; 371(2):107-18. PubMed ID: 24881463
[TBL] [Abstract][Full Text] [Related]
7. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
[TBL] [Abstract][Full Text] [Related]
8. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
9. Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers.
Vaz-Luis I; Francis PA; Di Meglio A; Stearns V
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-15. PubMed ID: 33989019
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Figg WD; Cook K; Clarke R
Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
[TBL] [Abstract][Full Text] [Related]
11. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
13. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
Bao T; Davidson NE
Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
Hubalek M; Brantner C; Marth C
Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
[TBL] [Abstract][Full Text] [Related]
17. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
Montagna E; Cancello G; Colleoni M
Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
[TBL] [Abstract][Full Text] [Related]
18. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
19. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
[TBL] [Abstract][Full Text] [Related]
20. Controversies in adjuvant endocrine treatment of premenopausal women.
Goldstein LJ
Clin Breast Cancer; 2006 Feb; 6 Suppl 2():S36-40. PubMed ID: 16595024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]